Twitter LinkedIn
    Saturday, April 1
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals & Transactions»Carlyle and Brighton Park agree to invest USD200m in Indegene
    Deals & Transactions

    Carlyle and Brighton Park agree to invest USD200m in Indegene

    February 4, 2021Updated:February 4, 20213 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    The Carlyle Group and Brighton Park Capital are to acquire minority stakes in  Indegene, a Bangalore-headquartered enterprise healthtech solutions provider, for USD200 million. 

    The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.

    Founded in 1998 by five first generation entrepreneurs, Indegene has emerged as the leading digital transformation partner to the global life sciences industry. With more than 3,000 employees across North America, Europe, China, Japan and India, Indegene provides technology platforms and commercialisation services to pharmaceutical, biotechnology, and medical device companies. Clients partner with Indegene to design, build, and manage digital-first operations that leverage data and automation to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success.

    Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programs. Decisions are increasingly data-driven and leading healthcare enterprises are seeking partners with strong domain knowledge and modern technology skills as a result. Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the primary investment from Carlyle and Brighton Park to accelerate its M&A and global expansion plans.

    Manish Gupta, Co-Founder and CEO of Indegene, says: “We are excited about our partnership with Carlyle and Brighton Park as their collective strengths will bring significant value to Indegene as we build on the deep domain knowledge and vertical technology we have developed over the past 20 years. Carlyle’s commitment to the healthcare sector with their global network and deep pharmaceutical expertise, coupled with Brighton Park’s deep experience in the technology sector and nuanced understanding of our space, makes the two firms the ideal partners to support our company’s continued growth.”

    Neeraj Bharadwaj, Managing Director of the Carlyle Asia advisory team, says: “We have been impressed by the strong entrepreneurial energy of the management team at Indegene and their technology-led, data driven, differentiated global delivery model, as well as by their ability to scale relationships with global healthcare enterprises. We believe this puts Indegene in a strong position to benefit from the significant growth drivers we are seeing in the healthcare space. We look forward to leveraging our global healthcare network and capabilities to help the company further strengthen and expand its portfolio while deepening relationships with its global client base.”

    Mark Dzialga, Managing Partner of Brighton Park Capital, says: “With a strong technology platform and a digital first approach, Indegene has established a reputation for high-quality content, analytics, and other healthcare solutions provided through a seamlessly integrated system. We have tremendous respect for Manish and the talented Indegene team, who have built the largest standalone digital transformation and commercialisation partner for healthcare enterprises globally. We are excited to partner with the company as we bring to bear our significant technology expertise to help accelerate Indegene’s global growth.”

    Over the last decade, Indegene has made significant organic and inorganic investments in building a technology portfolio that caters exclusively to healthcare. This has enabled the company to grow at more than 25 per cent revenue CAGR over a decade. This growth rate is accelerating with strong industry tailwinds driving a rapid shift towards digital-first operations.

    Torreya, Seyfarth Shaw, Deloitte, KPMG and Tatva Legal advised Indegene on this transaction. Moelis & Company, EY, Shardul Amarchand Mangaldas & Company, Latham & Watkins and Bain & Company acted as advisors for Carlyle. Brighton Park Capital was advised by EY, Paul Weiss and Bharucha & Partners.

    Source: Private Equity Wire 
    Image source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    deals and transactions Investments
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Thyssenkrupp shares move higher on report of CVC interest in steel unit

    March 21, 2023

    BlackRock Not Working on Rival Bid for Credit Suisse

    March 18, 2023

    University of California invests $4 bn in redemption-stricken REIT

    January 3, 2023

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    Comments are closed.

    Other Articles

    Private equity firm Livingbridge takes majority stake of Jungle Creations

    August 25, 2021

    Suez Gets Proposal From Ardian, GIP for Friendly Takeover

    January 17, 2021

    Babylon goes public in the US and secures investment from Palantir

    June 8, 2021

    Liverpool FC owner FSG seeks new teams and possible listing

    April 5, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?